Patents Assigned to Phylogica Limited
-
Patent number: 10288601Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.Type: GrantFiled: December 11, 2017Date of Patent: May 14, 2019Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Patent number: 9880151Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.Type: GrantFiled: May 23, 2012Date of Patent: January 30, 2018Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Patent number: 9567373Abstract: The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The libraries can be highly diverse such that they are representative of the repertoire of protein structures existing in nature. The libraries can also be non-redundant or normalized such that the bias towards specific structures existing in source data sets and/or in nature is/are removed. In a particularly preferred embodiment, the present invention provides 30,000 independent fold structures produced by this method. The present invention also provides computer-readable media and systems comprising structural data in relation to the peptide libraries, and methods for displaying and screening the libraries.Type: GrantFiled: September 26, 2013Date of Patent: February 14, 2017Assignee: Phylogica LimitedInventors: Paul Michael Watt, Roland Dunbrack
-
Publication number: 20150105274Abstract: The present invention relates to improved and integrated methods for the characterisation of an interaction site on a target protein that modulates the phenotype of a mammalian cell, such as a phenotype other than death and/or reduced growth. Such methods of the present invention include those to identify a target protein modulates such a phenotype of a mammalian cell, and optionally to characterise an interaction site on said target protein. Such identification and characterisation methods are useful in the development of research tools and/or therapeutics, such protein/peptide or small molecule therapeutics. Accordingly, the present invention also relates to methods of: identification of a ligand, such as a small molecule ligand, that binds to such a target protein; and identification a compound being a candidate modulator of said phenotype of a mammalian cell.Type: ApplicationFiled: February 7, 2013Publication date: April 16, 2015Applicants: Phylogica Limited, Cambridge Enterprise LimitedInventors: Paul Watt, Bryn Hardwick, Grahame McKenzie, Ashok Venkitaraman
-
Patent number: 8946381Abstract: The present invention provides a topical composition comprising (i) an amount of an AP-1 signaling inhibitor sufficient to reduce, delay or prevent apoptosis and/or necrosis induced by dermal wounding and/or to induce and/or enhance proliferation of a cell; and (ii) a suitable carrier or excipient e.g., a topical carrier or excipient or other carrier or excipient for dermal application. For example, the AP-1 signaling inhibitor is a peptide analog comprising the sequence set forth in SEQ ID NO: 104. The present invention also provides a method of treating a dermal wound comprising topically administering said topical composition to a subject suffering from a dermal wound.Type: GrantFiled: February 6, 2007Date of Patent: February 3, 2015Assignees: Phylogica Limited, The McComb Foundation, Inc.Inventors: Mark Fear, Paul Watt, Richard Hopkins, Nadia Milech
-
Patent number: 8822409Abstract: Polypeptides are identified through an assay based on inhibiting AP-I signalling activity and others to treat acute respiratory distress syndrome (ARDS) and clinical disorders associated with the development of ARDS.Type: GrantFiled: June 20, 2008Date of Patent: September 2, 2014Assignee: Phylogica LimitedInventors: Nadia Marian Dorothy Milech, Paul Michael Watt, Patrick G. Holt, Deborah Strickland
-
Patent number: 8802634Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: GrantFiled: July 13, 2009Date of Patent: August 12, 2014Assignee: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20140141452Abstract: The present invention provides a method of determining or identifying or isolating a cell-penetrating peptide (CPP) or analog or derivative thereof having cell-type selectivity and/or at least capable of passing through a Blood Brain Barrier of an animal subject. This invention also provides CPPs and analogs and derivatives thereof, such as those set forth in SEQ ID NOs: 1-27 of the Sequence Listing, and compositions comprising one or more of the CPPs, including conjugates in which a CPP or analog or derivative thereof is linked to a cargo molecule. The invention also provides methods for transporting cargo molecules across cell membranes to specific locations within cells, and for treating, preventing and/or diagnosing diseases that are treatable by a cargo molecule to which a CPP or analog or derivative of the invention is attached. The invention also provides tailored peptide libraries for use in identifying or isolating CPPs.Type: ApplicationFiled: May 23, 2012Publication date: May 22, 2014Applicant: Phylogica LimitedInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffman
-
Publication number: 20140128268Abstract: The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The libraries can be highly diverse such that they are representative of the repertoire of protein structures existing in nature. The libraries can also be non-redundant or normalized such that the bias towards specific structures existing in source data sets and/or in nature is/are removed. In a particularly preferred embodiment, the present invention provides 30,000 independent fold structures produced by this method. The present invention also provides computer-readable media and systems comprising structural data in relation to the peptide libraries, and methods for displaying and screening the libraries.Type: ApplicationFiled: September 26, 2013Publication date: May 8, 2014Applicant: Phylogica LimitedInventors: Paul Michael Watt, Roland Dunbrack
-
Patent number: 8575070Abstract: The present invention provides the means for producing libraries of peptide structures for drug screening applications that are capable of folding or assuming their native conformations independently of artificial scaffolds or flanking sequences in the proteins from which they are derived. The libraries can be highly diverse such that they are representative of the repertoire of protein structures existing in nature. The libraries can also be non-redundant or normalized such that the bias towards specific structures existing in source data sets and/or in nature is/are removed. In a particularly preferred embodiment, the present invention provides 30,000 independent fold structures produced by this method. The present invention also provides computer-readable media and systems comprising structural data in relation to the peptide libraries, and methods for displaying and screening the libraries.Type: GrantFiled: February 7, 2007Date of Patent: November 5, 2013Assignee: Phylogica LimitedInventors: Paul Michael Watt, Roland Dunbrack
-
Publication number: 20130266605Abstract: The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signaling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-Cd40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules.Type: ApplicationFiled: September 16, 2011Publication date: October 10, 2013Applicant: PHYLOGICA LIMITEDInventors: Paul Michael Watt, Richard Hopkins, Katrin Hoffmann
-
Publication number: 20120178649Abstract: The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid fragments of the libraries are derived from two or more diverse characterized genomes.Type: ApplicationFiled: July 15, 2011Publication date: July 12, 2012Applicant: Phylogica LimitedInventors: Paul M. Watt, Wayne Thomas, Richard Hopkins
-
Patent number: 8063012Abstract: The present invention provides AP-1 signaling inhibitory peptides of SEQ ID NOS:54-57, compositions of the peptides, and methods of treatment of neurological disorders by administration of the peptide(s) or compositions.Type: GrantFiled: January 31, 2007Date of Patent: November 22, 2011Assignee: Phylogica LimitedInventors: Paul Watt, Nadia Milech, Mark Fear
-
Publication number: 20110218118Abstract: The present invention provides a non-hybrid screening method for the identification and/or isolation of a peptide that is capable of modulating a phenotype in a cell, tissue or organism. For example, the non-hybrid screening method identifies a peptide that is derived from an organism that is unrelated to the cell, tissue or organism. Alternatively, or in addition, the non-hybrid screening method identifies a peptide that is capable of rescuing the cell, tissue or organism from cell death or inducing a cell, tissue or organism to grow. The present invention also provides a non-hybrid screening method for identifying a peptide that is useful for treating a disease and/or disorder.Type: ApplicationFiled: June 3, 2005Publication date: September 8, 2011Applicant: PHYLOGICA LIMITEDInventors: Paul M. Watt, Richard Hopkins, Mark Fear, Nadia M. D. Milech
-
Patent number: 7803765Abstract: The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid.Type: GrantFiled: February 20, 2004Date of Patent: September 28, 2010Assignee: Phylogica LimitedInventors: Paul Michael Watt, Wayne Robert Thomas, Richard Hopkins
-
Publication number: 20100029552Abstract: The present invention provides a method for the screening of nucleic acid fragment expression libraries and selecting encoded peptides based upon their ability to modulate the activity of a target protein or nucleic acid and assume conserved conformations compatible with albeit not reiterative of the target protein or nucleic acid. The present invention also provides methods for the diagnosis and treatment of ischemia. The present invention also provides c-Jun dimerization inhibitory peptides and analogues thereof that are useful for treatment of ischemia.Type: ApplicationFiled: August 22, 2005Publication date: February 4, 2010Applicant: Phylogica LimitedInventors: Paul Michael Watt, Mark Fear
-
Publication number: 20090170722Abstract: The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid fragments of the libraries are derived from two or more diverse characterized genomes.Type: ApplicationFiled: June 1, 2007Publication date: July 2, 2009Applicant: Phylogica LimitedInventors: Paul M. Watt, Wayne Thomas, Richard Hopkins
-
Patent number: 7270969Abstract: The present invention provides novel methods for producing nucleic acid fragment libraries that express highly diverse peptides or protein domains and, in particular, methods for producing nucleic acid fragment libraries wherein the nucleic acid fragments of the libraries are derived from two or more diverse characterized genomes.Type: GrantFiled: February 21, 2003Date of Patent: September 18, 2007Assignee: Phylogica LimitedInventors: Paul Michael Watt, Wayne Robert Thomas, Richard Hopkins
-
Publication number: 20070031832Abstract: Methods for producing nucleic acid fragment libraries that express highly diverse peptide domains, wherein the nucleic acid fragments are derived form microorganisms or eukaryotes with compact genomes. Also peptides derived form the libraries wherein the peptides are selected on the basis of their abilities to bind selected target proteins, including c-jun and antibodies raised against dust mite allergens.Type: ApplicationFiled: February 20, 2004Publication date: February 8, 2007Applicant: Phylogica LimitedInventors: Paul Watt, Wayne Thomas, Richard Hopkins
-
Patent number: 6994982Abstract: The present invention provides a method for identifying a modulator or mediator of a biological activity, which activity includes antigenicity and or immunogenicity, said method comprising the step of: (i) producing a gene fragment expression library derived from defined nucleotide sequence fragments; and (ii) assaying the expression library for at least an amino acid sequence derived from step (i) for a biological activity wherein that activity is different from any activity the amino acid sequence may have in its native environment.Type: GrantFiled: May 5, 2000Date of Patent: February 7, 2006Assignee: Phylogica LimitedInventors: Paul Michael Watt, Wayne Robert Thomas